Appili Therapeutics Inc. (OTCMKTS:APLIF) Sees Large Increase in Short Interest

Appili Therapeutics Inc. (OTCMKTS:APLIF) saw a significant increase in short interest during the month of June. As of June 15th, there was short interest totaling 25 shares, an increase of ? from the May 31st total of 0 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 8,277 shares, the short-interest ratio is presently 0.0 days.

Appili Therapeutics Price Performance

Shares of OTCMKTS APLIF opened at $0.01 on Tuesday. The firm’s 50-day moving average is $0.01 and its two-hundred day moving average is $0.01. The company has a market capitalization of $1.50 million, a PE ratio of -0.38 and a beta of -0.06. Appili Therapeutics has a 12-month low of $0.01 and a 12-month high of $0.03.

Appili Therapeutics (OTCMKTS:APLIF) last issued its quarterly earnings data on Friday, June 26th. The company reported $999.00 earnings per share for the quarter.

Appili Therapeutics Company Profile

Appili Therapeutics Inc is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada. The company specializes in the development and commercialization of novel anti-infective therapies designed to address both endemic and emerging infectious disease threats. Appili’s strategic focus includes small-molecule antibiotics, antivirals and vaccine adjuvants, with an emphasis on formulations suitable for rapid deployment in resource-limited or outbreak settings.

Appili’s product pipeline features multiple candidates in various stages of development.